File(s) under embargo
Reason: Awaiting publication
until file(s) become available
Using intradermal injection of lentiviruses to functionally validate Cep350 as a haploinsufficient melanoma tumor suppressor gene in vivo | Datasets Supporting: Tumor Suppressive Functions of CEP350 in Cutaneous Melanoma Cells
mediaposted on 15.07.2020, 20:57 by Michael Mann
Intradermal injection of shCEP350 and crCEP350 containing lentivirus particles into BrafV600E nevi drives primary cutaneous melanoma in immune component mice.
Supplementary datasets and other information accompanying manuscript: Tumor Suppressive Functions of CEP350 in Cutaneous Melanoma Cells by Aziz Aiderus, Bin Fang, John M. Koomen and Michael B. Mann.
Abstract: We previously identified Cep350 as a novel melanoma haploinsufficient melanoma tumor suppressor gene using SB transposon-mediated mutagenesis to drive melanoma progression in Braf(V600E) mutant (SB|Braf) mice functionally demonstrated that the human CEP350 ortholog is a new melanoma tumor-suppressor gene in human cancer cell lines (Mann et al., Nature Genetics, 2015). Further dissection of the latent tumor suppressive functions of CEP350 in cutaneous melanoma cells is essential for understanding its role in melanoma imitation and progression. In this work, we investigated the role of the novel tumor suppressive functions of CEP350 in cutaneous melanoma cells using comparative informatics, molecular oncology, and proteomics approaches to demonstrate that CEP350 acts via altered cytoskeletal dynamics to contribute to BRAF-V600E driven melanoma.
Moffitt Cancer Center Support Grant
National Cancer InstituteFind out more...
Select an IC:
- CA - National Cancer Institute (NCI)